Hypertension With Psoriasis Tied to More Cardiac Interventions
In patients with hypertension, psoriasis linked to increased risk for cardiovascular procedures, surgeries.
Psoriasis Information Center
Novel Scoring System Can Up Access to Biologics in Psoriasis
DLQI-R allows more patients to achieve threshold for becoming candidates for biologic treatment.
Psoriasis Linked to Increased Risk for Inflammatory Bowel Disease
Psoriasis appears to be significantly associated with inflammatory bowel disease.
Alternative Medicines May Aid in the Treatment of Psoriasis
Most studies evaluated fish oil, acupuncture, indigo naturalis, curcumin, meditation.
Psoriasis Treatment With Biologics Often Requires Multiple Courses, Treatment Changes
The final analysis set comprised biologic-naïve individuals — individuals who had filled an initial prescription for etanercept, infliximab, adalimumab, or ustekinumab after 2 years without using any biologic agent during the study period.
Comorbidity risks increase in children with psoriasis
Some of the comorbidities include increased lipid levels, hypertension, and diabetes.
Methotrexate vs tumor necrosis factor inhibitors for pediatric psoriasis
Medication-related adverse events occur more frequently with methotrexate in children with moderate to severe psoriasis.
Severe psoriasis linked to higher mortality risk
Patients with psoriasis whose disease affects >10% of their body surface area (BSA) are at an increased risk for death compared with the general population.
Sleep disturbance in psoriasis leads to psychological and physical predictors
Sleep complaints among individuals with psoriasis warrant greater clinical attention, as they have a greater chance for developing obstructive sleep apnea.
Psoriasis patients have an increased risk of alcohol-related mortality
Patients with psoriasis have a greater risk of mortality due to alcohol-related causes, including alcoholic liver disease, fibrosis and cirrhosis of the liver, and mental and behavioral disorders.
Secukinumab well-tolerated in patients with scalp psoriasis
This study shows that more than 50% of patients can expect a 90% or greater improvement in scalp psoriasis within 12 weeks.
Smoking may be a risk factor for psoriasis
Researchers observed a positive correlation between the amount and duration of smoking and the occurrence of psoriasis.
Biosimilar ABP 501 and adalimumab safe and effective for plaque psoriasis
Biosimilar ABP 501 has similar clinical efficacy and safety to adalimumab for the treatment of plaque psoriasis.
Dalazatide effective for skin lesions in plaque psoriasis
Dalazatide treatment reduced the plasma levels of multiple inflammation markers and reduced the expression of T cell activation markers on peripheral blood memory T cells.
Screening guidelines for pediatric psoriasis comorbidities
The guidelines are the first to provide recommendations for comorbidity screening in pediatric psoriasis patients.
Cardiometabolic comorbidity rates high in psoriasis patients
The most common comorbidities found in patients with psoriasis are hyperlipidemia, hypertension, depression, type 2 diabetes mellitus, and obesity.
Biologic treatment for psoriasis shows long-term effectiveness
Researchers sought to analyze long-term and real-world outcome data in patients with moderate-to-severe psoriasis after starting biologic treatment.
First-line biologic treatment for psoriasis influenced by specific factors
Presence of psoriatic arthritis, weight, employment status, baseline disease severity affect the selection of first-line biologic treatment.
High fatigue common in psoriatic arthritis
Nearly 50% of patients with psoriatic arthritis report elevated levels of fatigue.
FDA approves Inflectra biosimilar for rheumatoid arthritis, psoriasis
The biosimilar has also been approved for Crohn’s disease, ulcerative colitis, and ankylosing spondylitis.
Want to read more?
Please login or register first to view this content.
Next post in Psoriasis Information Center
